TaiwanJ planning Phase II/III for autoimmune hepatitis candidate following Phase II readout

TaiwanJ Pharmaceuticals Co. Ltd. (TPEx-E:6549) said once-daily oral JKB-122 for 24 weeks met the

Read the full 148 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE